• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生存分布影响随机安慰剂阶段设计和平行组随机临床试验的功效。

Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trials.

机构信息

Child Health Evaluative Sciences Program, The Hospital for Sick Children Research Institute, University of Toronto, Toronto, Ontario MSG 1X8, Canada.

出版信息

J Clin Epidemiol. 2011 Mar;64(3):286-92. doi: 10.1016/j.jclinepi.2010.02.021. Epub 2010 Oct 6.

DOI:10.1016/j.jclinepi.2010.02.021
PMID:20926258
Abstract

OBJECTIVES

The study evaluated the power of the randomized placebo-phase design (RPPD)-a new design of randomized clinical trials (RCTs), compared with the traditional parallel groups design, assuming various response time distributions. In the RPPD, at some point, all subjects receive the experimental therapy, and the exposure to placebo is for only a short fixed period of time.

STUDY DESIGN AND SETTING

For the study, an object-oriented simulation program was written in R. The power of the simulated trials was evaluated using six scenarios, where the treatment response times followed the exponential, Weibull, or lognormal distributions. The median response time was assumed to be 355 days for the placebo and 42 days for the experimental drug.

RESULTS

Based on the simulation results, the sample size requirements to achieve the same level of power were different under different response time to treatment distributions. The scenario where the response times followed the exponential distribution had the highest sample size requirement. In most scenarios, the parallel groups RCT had higher power compared with the RPPD.

CONCLUSION

The sample size requirement varies depending on the underlying hazard distribution. The RPPD requires more subjects to achieve a similar power to the parallel groups design.

摘要

目的

本研究评估了随机安慰剂阶段设计(RPPD)——一种新的随机临床试验(RCT)设计,与传统的平行组设计相比,假设了各种反应时间分布。在 RPPD 中,在某个时间点,所有受试者都接受实验治疗,而接受安慰剂的暴露时间仅为固定的短时间。

研究设计和设置

为此研究,我们用 R 编写了一个面向对象的模拟程序。使用六种情景评估模拟试验的功效,其中治疗反应时间遵循指数、威布尔或对数正态分布。假设安慰剂的中位反应时间为 355 天,实验药物的中位反应时间为 42 天。

结果

根据模拟结果,在不同的治疗反应时间分布下,实现相同功效水平所需的样本量要求不同。反应时间遵循指数分布的情景需要最大的样本量要求。在大多数情况下,平行组 RCT 的功效比 RPPD 更高。

结论

样本量要求取决于潜在的风险分布。RPPD 需要更多的受试者才能达到与平行组设计相似的功效。

相似文献

1
Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trials.生存分布影响随机安慰剂阶段设计和平行组随机临床试验的功效。
J Clin Epidemiol. 2011 Mar;64(3):286-92. doi: 10.1016/j.jclinepi.2010.02.021. Epub 2010 Oct 6.
2
Sample size determination and statistical power in randomized controlled trials.随机对照试验中的样本量确定与统计效能
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 May;109(5):652-3. doi: 10.1016/j.tripleo.2010.01.013.
3
Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints.比较终止设计与经典随机设计在事件发生时间终点方面的效能。
Control Clin Trials. 2004 Apr;25(2):168-77. doi: 10.1016/j.cct.2003.11.005.
4
Improving the design of phase II trials of cytostatic anticancer agents.改进细胞抑制性抗癌药物II期试验的设计。
Contemp Clin Trials. 2007 Feb;28(2):138-45. doi: 10.1016/j.cct.2006.05.009. Epub 2006 Jul 14.
5
An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.精神科临床试验中序贯平行设计的效率考察
Clin Trials. 2007;4(4):309-17. doi: 10.1177/1740774507081217.
6
The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.临床医生作为研究者:在实际临床环境中参与临床试验:附录2:研究设计与分析中的统计学概念
Circulation. 2004 Jun 1;109(21):e305-7. doi: 10.1161/01.CIR.0000129020.43304.A7.
7
Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.精神分裂症随机非典型抗精神病药物试验中的对照组偏倚。
Arch Gen Psychiatry. 2005 Sep;62(9):961-70. doi: 10.1001/archpsyc.62.9.961.
8
Design and sample size estimation in clinical trials with clustered survival times as the primary endpoint.以聚类生存时间为主要终点的临床试验中的设计与样本量估计
Stat Med. 2003 Sep 30;22(18):2835-46. doi: 10.1002/sim.1536.
9
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.抗精神病药物安慰剂对照和活性对照临床试验中的脱落率:一项荟萃分析。
Arch Gen Psychiatry. 2005 Dec;62(12):1305-12. doi: 10.1001/archpsyc.62.12.1305.
10
Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials.从过去的错误中学习:评估非肾性系统性红斑狼疮随机对照试验的试验质量、效能和入选标准。
Rheumatology (Oxford). 2008 Sep;47(9):1367-72. doi: 10.1093/rheumatology/ken230. Epub 2008 Jun 24.

引用本文的文献

1
Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases.采用元叙述文献回顾和焦点小组访谈的方法,让关键利益相关者参与,以确定在生成罕见病治疗效果的可靠证据方面,人们认为存在哪些挑战和解决方案。
Orphanet J Rare Dis. 2018 Jun 28;13(1):104. doi: 10.1186/s13023-018-0851-1.
2
Systemic Sclerosis Trial Design Moving Forward.系统性硬化症试验设计正在推进。
J Scleroderma Relat Disord. 2016 May-Aug;1(2):177-180. doi: 10.5301/jsrd.5000198. Epub 2018 Jan 23.
3
Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease.
对延迟启动设计论点的批判性评价,该设计被提议作为罕见病领域中平行组随机临床试验设计的替代方案。
Orphanet J Rare Dis. 2017 Aug 17;12(1):140. doi: 10.1186/s13023-017-0692-3.
4
Understanding the value of information from pediatric clinical research.理解儿科临床研究信息的价值。
Paediatr Drugs. 2012 Oct 1;14(5):295-7. doi: 10.2165/11640510-000000000-00000.